Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
News|Videos|May 22, 2023
Evolution of Pharmacological Treatments at the 2023 APA Annual Meeting
Author(s)John J. Miller, MD
An inside look at what treatments are being discussed in San Francisco...
Advertisement
CONFERENCE REPORTER
What exciting treatments are being discussed at the APA Annual meeting this year? Psychiatric Times Editor-in-Chief, John J. Miller, MD, gives an overview.
What new treatments are you interested in? Let us know at
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
Advertisement
Advertisement
Trending on Psychiatric Times
1
How Best to Manage Treatment-Resistant Depression
2
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
3
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
4
Podcast: Using Antipsychotic Plasma Levels to Guide Schizophrenia Treatment With Jonathan M. Meyer, MD
5